Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet

Uncategorized
  1. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial  The Lancet
  2. Chlamydia vaccine moves a step closer  The Guardian
  3. Chlamydia vaccine shown to be safe in first ever human trial  New Scientist
  4. Chlamydia sex infection vaccine passes safety test  BBC News
  5. Chlamydia vaccine shows promise in early tests  Bangkok Post
  6. View full coverage on Google News


Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet
Source: Nigerian Healthcare Blog

The Academic Clinic - Leave Comments

Tagged

Review Overview

Summary